Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

Our blood consists of many cell types that develop through different stages from a precursor type—the blood stem cell. An ...

Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and faculty member in the Department of Anatomy, led a study investigating the ...

Most people exposed to the parasites behind babesiosis don't get sick, but for others, the infection can be deadly.

Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and faculty member in the Department of Anatomy, recently led a study investigating ...

Did you know that donating blood can do more than just save a life? Here's what your blood can tell you about your health.

is a measurement of the average amount of hemoglobin within a red blood cell. MCH that's lower or higher than normal may indicate you have a condition such as anemia or high cholesterol.

“Immunoglobulins recognise dangerous micro-organisms and help the immune cells to neutralise them. It’s a vital treatment for people with immune disorders. “We urge people in Cornwall to try blood ...

SYDNEY, Australia — James Harrison, a prolific Australian blood donor famed for having saved the lives of more than 2 million babies, has died at age 88. Harrison, whose plasma contained a "rare ...

To overcome this, herein blood cells were used as they are easy and routinely to isolate. Within this study we provide detailed protocols for determination of the autophagic flux in peripheral blood ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.